Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Oppenheimer

Gilead Sciences (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a research note issued to investors on Friday, Benzinga reports. They presently have a $105.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 57.28% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Royal Bank of Canada reduced their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Mizuho reduced their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. UBS Group reduced their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Wells Fargo & Company dropped their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $66.76 on Friday. Gilead Sciences has a 1-year low of $65.90 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business has a fifty day moving average price of $71.96 and a 200-day moving average price of $76.56. The company has a market capitalization of $83.12 billion, a PE ratio of 14.84, a PEG ratio of 0.91 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the previous year, the business earned $1.67 earnings per share. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences will post 6.55 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GILD. PCA Investment Advisory Services Inc. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $25,000. OFI Invest Asset Management bought a new stake in Gilead Sciences in the 3rd quarter worth approximately $26,000. Tompkins Financial Corp increased its stake in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $29,000. Finally, Private Wealth Management Group LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $29,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.